<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378284</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_108</org_study_id>
    <nct_id>NCT03378284</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Active-controlled, Multiple Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, and Pharmacodynamics of Tegoprazan After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, active-controlled, multiple dose phase 1 clinical trial to evaluate
      safety, tolerability, and pharmacodynamics of tegoprazan after oral administration in healthy
      male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To compare the pharmacodynamics of multiple oral dose of tegoprazan versus the
           pharmacodynamics of multiple oral dose of comparator drug in healthy male volunteers.

        -  To evaluate the safety and tolerability of multiple oral dose of tegoprazan in healthy
           male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2017</start_date>
  <completion_date type="Actual">January 16, 2018</completion_date>
  <primary_completion_date type="Actual">December 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric pH</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Gastric pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum gastrin concentration</measure>
    <time_frame>up to 9 days</time_frame>
    <description>Serum gastrin concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Pharmacodynamics</condition>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Tegoprazan(Test drug)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan drug QD for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator drug QD for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan</intervention_name>
    <description>Tegoprazan QD for 7 days</description>
    <arm_group_label>Tegoprazan(Test drug)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revaprazan</intervention_name>
    <description>Revaprazan QD for 7 days</description>
    <arm_group_label>Active comparator drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged ≥ 19 years and ≤ 50 years

          -  Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.0 kg/m2 and
             ≤ 27.0 kg/m2 at the time of screening

        Exclusion Criteria:

          -  Presence or history of clinically significant diseases

          -  Presence or history of gastrointestinal disorder (gastric ulcer, GERD, Crohn's
             disease, etc.)

          -  Hypersensitivity to drugs containing study drug or proton pump inhibitor and other
             drugs (aspirin, antibiotics, etc.) or history of clinically significant
             hypersensitivity

          -  Serologic test positive

          -  Abnormal obstacle to insertion and maintenance of pH meter catheter

          -  History of drug abuse

          -  Excessive caffeine intake or persistent alcohol intake

          -  Not use of a medically acceptable method of contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

